Ann: Quarterly Report and Appendix 4C, page-35

......or you could look at the report in full to make an assessment of value. 
Certainly revenues matter, but so does the effect of the US farm bill delay, and the opportunities it represents.  As well there is  entry into the NZ market; far advanced in medicinal cannabis market compared to Aus.  Then there is Japan, Europe and work being done in the Australian marketplace.  A lot of advertising alluded to in the report - a higher cost in the initial phase of brand recognition, but truly an investment.   
Really - all in all - a good report, and for those looking to the future of this company very encouraging.  
Would be a bit surprised if this dropped further, and far less surprised if it made up some ground quickly.